Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7483.091 | 0.9546 | 0.9697 | 3.0465 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7483.091 | 0.9433 | 0.9621 | 3.0465 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7483.091 | 1.0032 | 1.0021 | 3.0465 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7483.091 | 0.9281 | 0.9516 | 3.0465 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7483.091 | 0.8883 | 0.9237 | 3.0465 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7483.091 | 0.0413 | -0.2975 | 3.0465 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7483.091 | 0.0119 | -0.5328 | 3.0465 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7484.09 | 0.9118 | 0.9316 | 2.6525 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7484.09 | 0.9395 | 0.9535 | 2.6525 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7484.09 | 0.9837 | 0.9877 | 2.6525 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7484.09 | 0.8957 | 0.9186 | 2.6525 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7484.09 | 0.9195 | 0.9377 | 2.6525 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7484.09 | 0.9770 | 0.9825 | 2.6525 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7484.09 | 0.6104 | 0.6604 | 2.6525 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7484.09 | 0.0119 | -0.6240 | 2.6525 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7484.09 | 0.0046 | -0.7365 | 2.6525 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7485.092 | 0.9296 | 0.9603 | 3.6408 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7485.092 | 1.0083 | 1.0045 | 3.6408 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7485.092 | 0.9461 | 0.9698 | 3.6408 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7485.092 | 0.9681 | 0.9823 | 3.6408 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7485.092 | 1.0060 | 1.0033 | 3.6408 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7485.092 | 0.9352 | 0.9635 | 3.6408 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7485.092 | 0.8294 | 0.8999 | 3.6408 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7485.092 | 0.0184 | -0.3322 | 3.6408 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7485.092 | 0.0039 | -0.5636 | 3.6408 |